CClinicalTrials.gg
Sign In
RecruitingNCT04183101Updated Jun 22, 2025

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

A Phase 2 interventional study of Aliskiren and Enalapril in C3 Glomerulopathy, Membranoproliferative Glomerulonephritis and Complement Abnormality, sponsored by Region Skane. Recruiting at 4 sites in Sweden. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-06-22.

Sponsored by Region Skane · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Study summary

The aim of this cross-over trial is to assess aliskiren, a direct renin inhibitor, as a novel treatment to block complement activation in the kidneys and thereby attenuate renal disease and stabilize or improve kidney function and compare it to the currently used treatment with the angiotensin converting enzyme inhibitor, enalapril, in patients with the complement-mediated renal disease C3 glomerulopathy. Patients will be randomized to one or the other treatment for the first 6 months and then switch to the other treament for the following 2.5 years. Treatment will continue for altogether 3 years for each patient.

Read the detailed description

The primary objective is to assess the effect and safety of aliskiren on reducing systemic and local complement activation as indicated by a reduction of serum C3 during the cross-over study and serum C3 and complement deposition in renal biopsies during the extension study in patients with C3 glomerulopathy as compared to the currently used treatment with the angiotensin converting enzyme inhibitor (ACEi) enalapril.

Secondary objectives are to assess the effect of aliskiren as compared to the currently used treatment with the ACEi enalapril on: complement activation (such as serum C3a, C3dg, C5a and related complement assays), proteinuria, kidney function, kidney biopsy findings, blood pressure, activation of the renin angiotensin system.

Aliskiren will be administered orally in tablet form at 150 -300 mg/daily (maximal dose 300 mg). Enalapril 2.5-20 mg/daily (maximal dose 20 mg). These drugs may be administered once or twice.

The investigators estimate an inclusion of maximum 15 patients for start of treatment with aliskiren and maximum 15 patients for start of treatment with enalapril. Suitable patients will be chosen from those patients who:

  1. Do not have severe renal failure. Pediatric patients will be included if they have a glomerular filtration rate ≥ 50 ml/min/1.73m2, adults ≥ 30 ml/min/1.73m2.
  2. Children, above the age of 6 years of age and adults.
  3. Patients treated with aliskiren will be compared to patients treated with the ACE inhibitor enalapril as monotherapy. Use of ACE inhibitor as a nephroprotective therapy will increase renin levels without blocking its effect. Thus, the investigators will compare patients on aliskiren with those on enalapril to investigate if ACE inhibition as monotherapy has a negative effect on complement activation in comparison to direct renin inhibition.
  4. Patients treated with immune suppressive medications at the start (such as mycophenolate mofetil (MMF) or corticosteroids) will be compared to patients treated with MMF or steroids plus aliskiren or enalapril.

All suitable patients who fulfill inclusion criteria and who submitted written informed consent (patient or patient's legal guardians) will have undergone a renal biopsy at the most 2 years before inclusion or at inclusion and will be randomized for treatment with aliskiren or enalapril. After 6 months patients on aliskiren will switch to enalapril and vice versa, patients on enalapril will switch to aliskiren treatment. Patients will be followed routinely, every 3rd month, regarding renal function (creatinine, urea, estimated glomerular filtration rate), albumin (blood and urine), renin levels and complement activation assays in blood samples (C3, C3dg, C5, properdin, soluble terminal complement complex, C3a, C5a, C3 nephritic factor and other complement assays). The follow-up period, a total of 3 years from the start, will be carried out by the patient's own nephrologist and will not differ from the clinical follow-up offered patients not participating in the study. After 1-3 years (when medically indicated but at the most 3 years after start), a repeat renal biopsy will be performed to validate the effect of treatment on renal morphology. Renal biopsies, both the initial and the repeat biopsy, will be evaluated for complement deposition and glomerular basement membrane thickness.

02

Conditions studied

  • C3 Glomerulopathy
  • Membranoproliferative Glomerulonephritis
  • Complement Abnormality
  • Dense Deposit Disease
  • C3 Glomerulonephritis
03

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Children ≥ 6 years and adults.
  2. Initial diagnosis of Dense Deposit Disease and C3 glomerulonephritis confirmed by kidney biopsy obtained not more than 2 years before the first dose of the study drug.
  3. Either absence of treatment at the study start or ongoing treatment with aliskiren, angiotensin converting enzyme inhibitors, angiotensin receptor blockers or immune suppressive medications (such as mycophenolate mofetil/MMF or corticosteroids)

  4. Written informed consent has been given by:

    1. the patient's legal guardians if the patient is less than 15 years old
    2. the patient and his/her legal guardians if the patient is ≥ 15 but \< 18 years old
    3. the patient, if the patient is ≥ 18 years old

  5. Female subjects of childbearing potential must:

    1. Understand that the study medication is expected to have a teratogenic risk

    2. Agree to use a highly effective contraceptive during study drug therapy. This applies unless the subject is less than 18 years of age, has not had sexual debut and commits to sexual abstinence confirmed by a pregnancy test on every study visit. Either of the following methods of contraception may be used:

      • Combined (estrogen and progesterone) hormonal contraception associated with inhibition of ovulation: oral, intravaginal or transdermal
      • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable or implantable
      • Intrauterine device
      • Intrauterine hormone-releasing system
      • Bilateral tubal occlusion
      • Vasectomized partner
      • Sexual abstinence
      • Male or female condom with or without spermicide
      • Cap, diaphragm or sponge with spermicide
    3. Agree to have a pregnancy test before the start of study medication. This requirement also applies to women of childbearing age who practice complete and continued abstinence and adolescent girls after menarche.
    4. Agree to have a pregnancy test every 3rd month including at the end of study treatment, except in the case of confirmed tubal sterilization. This requirement also applies to women of childbearing age who practice complete and continued abstinence and adolescent girls after menarche.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to aliskiren, ACEi or substances contained in these preparations.
  2. Angioedema caused by aliskiren or enalapril
  3. Weight \< 25 kg
  4. Glomerular filtration rate ≤ 50 ml/min/1.73 m2 (measured by iohexol clearance) in children and ≤ 30 ml/min/1.73 m2 in adults.
  5. Rapid deterioration of kidney function during the latest year of the disease
  6. Patients with a renal transplant
  7. Immune complex-mediated membranoproliferative glomerulonephritis (such as in HIV infection, hepatitis, SLE)
  8. Females who breastfeed, are pregnant or planning to become pregnant during the study.
  9. Co-morbidity such as malignancy, congestive heart failure, recent myocardial infarction.
  10. Mental incapacity or language barriers to understand the contents of the study design.
  11. Simultaneous use of another complement-antagonist (such as eculizumab). Eculizumab must be discontinued and complement activity normalized before the start of study drug.
  12. Simultaneous use of aliskiren or enalapril with cyclosporine or nonsteroidal anti-inflammatory drugs (NSAID).
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Aliskiren treatment

    Patients will be randomized to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for 6 months. After 6 months the patients will be switched to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for the coming 2,5 years.

    Drug: Aliskiren

  • Active comparator
    Enalapril treatment

    Patients will be randomized to tablet treatment with enalapril (target daily dose 7.5-20 mg once or twice a day) for 6 months. After 6 months the patients will be switched to tablet treatment with aliskiren (target daily dose) 150-300 mg once daily or every other day (depending on weight) for the coming 2,5 years.

    Drug: Enalapril

Interventions

  • DrugAliskiren

    Patients will be randomized to start treatment with aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight. After 6 months switch to enalapril 2.5-20 mg daily and continue with that 2.5 years.

    Also known as: Enalapril

  • DrugEnalapril

    Patients will be randomized to start with enalapril 2.5-20 mg daily depending on weight. After 6 months switch to aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight and continue with this treatment for 2.5 years.

    Also known as: Aliskiren

05

What researchers measure

Primary outcomes

  1. C3 levels in serum

    To assess the effect and safety of aliskiren as compared to enalapril on reducing systemic complement activation as assayed by C3 levels in serum.

    Time frame: 3 years

  2. Complement deposition in kidneys

    To quantify complement deposition in kidney biopsies from patients with C3 glomerulopathy using immunohistological staining

    Time frame: 3 years

Secondary outcomes

  1. C3a in serum

    To assess the effect of aliskiren compared to currently used treatment with the ACEi enalapril on C3a in serum

    Time frame: 3 years

  2. C3dg in plasma

    To assess the effect of aliskiren compared to currently used treatment with the ACEi enalapril on C3dg in plasma

    Time frame: 3 years

  3. C5a in serum

    To assess the effect of aliskiren compared to currently used treatment with the ACEi enalapril on C5a in serum

    Time frame: 3 years

  4. Glomerular basement membrane thickness

    To assess the effect of aliskiren compared to currently used treatment with the ACEi enalapril on glomerular basement membrane thickness assessed by electron microscopy measurement

    Time frame: 3 years

  5. Proteinuria

    To assess the effect of aliskiren compared to currently used treatment with the ACEi enalapril on protein levels in urine measured as the ratio between albumin/creatinine in urine

    Time frame: 3 years

Other outcomes

  1. Renal function

    To assess the effect of aliskiren compared to currently used treatment with the ACEi enalapril on kidney function measured as iohexol clearance glomerular filtration rate

    Time frame: 3 years

06

Study locations

1 of 4 sites recruiting
07

References and documents

Publications

  • Bekassy ZD, Kristoffersson AC, Rebetz J, Tati R, Olin AI, Karpman D. Aliskiren inhibits renin-mediated complement activation. Kidney Int. 2018 Oct;94(4):689-700. doi: 10.1016/j.kint.2018.04.004. Epub 2018 Jun 5. PubMed 29884545 ↗
  • Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, Fremeaux-Bacchi V, Jozsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Cordoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019 Mar;15(3):129-143. doi: 10.1038/s41581-018-0107-2. PubMed 30692664 ↗
  • Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000 May;57(5):1803-17. doi: 10.1046/j.1523-1755.2000.00031.x. PubMed 10792600 ↗

Individual participant data

Plan to share: Yes — The study and de-identified data will be shared with study coordinators at various sites

Supporting information: Study protocol, Sap, Icf, Csr

08

Registry details

Key details

Study ID
NCT04183101
Lead sponsor
Region Skane
Responsible party
Sponsor
First posted
Dec 3, 2019
Start date
Oct 1, 2020
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jun 22, 2025

Study contacts

Diana Karpman, MD PhD
Contact
diana.karpman@med.lu.se
+46-46-2220747
Zivile Bekassy, MD PhD
Contact
zivile.bekassy@med.lu.se
Diana Karpman
principal investigator · Region Skåne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Glomerulonephritis→

Other studies from this sponsor

Region Skane

Start the discussion